LACE+ and MRS Score Readmission Rate Assessment

Sponsor

Tabula Rasa HealthCare (Industry)

Overall Status

Terminated

CT.gov ID

NCT04365673

Collaborator

(none)

100

Enrollment

Location

7.8

Actual Duration (Months)

12.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A study to demonstrate that the LACE+ score in non-inferior to the medication risk score when predicting 30-day readmission post hospital discharge.

Condition or Disease	Intervention/Treatment	Phase
Hospitalism	Other: Pharmacist transition of care consultation

Detailed Description

The objective of this study is evaluate a program that provides transition of care services to a local Tucson hospital involving activities designed to reduce 30 day post hospital discharge readmission rates. The organization has had a fee for service contract with this hospital since 2017 to provide pharmacist delivered transition of care services. The organization collects internal tracking outcome data as part of the contract deliverable and is required to report it to the hospital once per month. The investigators look to assess LACE+ and medication risk scores to learn if there is an association with the 30 day post hospital discharge readmission rate post pharmacist intervention. The outcomes will not be generalizable and will be reported back to the hospital client to demonstrate value added.

Study Design

Study Type:

Observational

Actual Enrollment :

100 participants

Observational Model:

Case-Control

Time Perspective:

Retrospective

Official Title:

Comparing the Predictive Strength of the LACE+ Index With the MedWise Rise Score on Hospital Readmission Rates: a Non-inferiority Observational Study

Actual Study Start Date :

Jul 7, 2020

Actual Primary Completion Date :

Mar 1, 2021

Actual Study Completion Date :

Mar 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Readmitted Patients that were readmitted within 30 days post hospital discharge	Other: Pharmacist transition of care consultation Pharmacist-delivered comprehensive medication review
Not readmitted Patients that were not readmitted within 30 days post hospital discharge	Other: Pharmacist transition of care consultation Pharmacist-delivered comprehensive medication review

Arm

Intervention/Treatment

Readmitted

Patients that were readmitted within 30 days post hospital discharge

Other: Pharmacist transition of care consultation

Pharmacist-delivered comprehensive medication review

Not readmitted

Patients that were not readmitted within 30 days post hospital discharge

Other: Pharmacist transition of care consultation

Pharmacist-delivered comprehensive medication review

Outcome Measures

Primary Outcome Measures

Readmission [2018 - 2019]
Readmission within 30-days post hospital discharge

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 88 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Those referred to receive transition of care services between January 2018 to December 2019 and were discharged on 10 or more medications.

Exclusion Criteria:

89 years or older

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Tabula Rasa HealthCare	Tucson	Arizona	United States	85701

Sponsors and Collaborators

Tabula Rasa HealthCare

Investigators

Principal Investigator: Jennifer Bingham, PharmD, Tabula Rasa HealthCare

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Tabula Rasa HealthCare

ClinicalTrials.gov Identifier:

NCT04365673

Other Study ID Numbers:

TRHC_RD_LACEMRS_2020

First Posted:

Apr 28, 2020

Last Update Posted:

Mar 17, 2022

Last Verified:

Mar 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD:

Undecided

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Tabula Rasa HealthCare

LACE

medication risk score

Study Results

No Results Posted as of Mar 17, 2022